Innovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Up 11.5% in October

Innovent Biologics, Inc. (OTCMKTS:IVBXFGet Rating) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 7,160,600 shares, an increase of 11.5% from the October 15th total of 6,420,100 shares. Based on an average daily trading volume, of 5,700 shares, the days-to-cover ratio is presently 1,256.2 days.

Innovent Biologics Price Performance

OTCMKTS IVBXF opened at $4.33 on Tuesday. Innovent Biologics has a 52 week low of $2.29 and a 52 week high of $10.16. The stock has a fifty day moving average of $3.59 and a 200-day moving average of $3.69.

About Innovent Biologics

(Get Rating)

Innovent Biologics, Inc operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma.

Read More

Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.